Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

Abstract

Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment. Introduction The primary aim of this study was the evaluation of serum sclerostin levels in postmenopausal women and their association with bone mineral density (BMD) and bone turnover markers. The secondary aim was the evaluation of treatment with either teriparatide (TPTD) or risedronate (RIS) on serum sclerostin levels in women with postmenopausal osteoporosis. Methods Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited. Main outcome measure was serum sclerostin levels.Results Serum sclerostin was higher in the NOEP group at baseline compared with either TPTD group (p = 0.007) or RIS group (p = 0.049). Sclerostin was positively correlated with both lumbar spinal (LS) BMD (r = 0.353; p = 0.005) and T-score (r = 0.501; p < 0.001) and negatively correlated with intact parathyroid hormone (r = −0.343; p = 0.024) at baseline. Multiple regression analysis showed that either LS BMD (Beta = 0.653; p = 0.018) or T-score (Beta = 0.711; p = 0.005) were independent predictors of serum sclerostin levels. No significant correlation was observed between serum sclerostin and bone turnover markers or estradiol at baseline. Sclerostin was significantly increased 6 months post-treatment in RIS group (p = 0.002), whereas remained statistically unaffected in the TPTD group. Conclusions Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6 months treatment with RIS, whereas remained essentially unchanged after 6 months TPTD treatment.

Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis

“…Thus, the possibility remains that 1,25(OH)2D3 links FGF23 to bone destruction and osteoporosis, which warrants investigation. Furthermore, sclerostin is a humoral factor that strongly inhibits bone formation (31) and elevated circulating levels of this factor are associated with the incidence of osteoporosis in postmenopausal women (32). Because sclerostin is also released from osteocytes (33), its net function may be indicated by circulating FGF23 levels, which may in turn be affected by osteocyte activity.…”

Expression of Fibroblast Growth Factor 23, Vitamin D Receptor, and Sclerostin in Bone Tissue from Hypercalciuric Stone Formers

“…Once again, given that Scl inhibits osteoblastic activity, a negative correlation would be expected. However, some studies have also found direct correlations between serum Scl and BMD (48,49) or BV/TV in healthy populations (50).…”

Impacto del tratamiento con teriparatida en la calidad de vida de las personas con osteoporosis

“…Para el análisis estadístico se utilizaron las técnicas de regresión lineal 13,28,29 y de regresión logística 1,4,18,20,21,23 con el uso del SPSS para Windows versión 16.…”